Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate

Autor: Alison O’Mahony, Markus R. John, Hannah Cho, Misato Hashizume, Ernest H. Choy

Publikováno v: Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-9 (2018)

Abstract Background Clinical trials have shown combinations of anti–tumor necrosis factor biologicals plus methotrexate (MTX) are more effective treatments for rheumatoid arthritis than biological monotherapies, based, in part, on the assumption th

Externí odkaz: https://doaj.org/article/7dea4c52ebb74545b01449c222eeade7

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions

Autor: Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B McInnes, Naveed Sattar, Tanja A Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée van der Heijde, Marieke Voshaar, Kevin L Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Rüdiger R Burmester, Johannes WJ Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H Choy, Catalin Codreanu, Bernard Combe, Mary K Crow, Maarten de Wit, Paul Emery, Roy M Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L Hyrich, Annamaria Iagnocco, John D Isaacs, Joel M Kremer, Xavier Mariette, Peter A Merkel, Eduardo F Mysler, Peter Nash, Michael T Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S Smolen

Publikováno v: Annals of the rheumatic diseases. BMJ
Aletaha, D, Kerschbaumer, A, Kastrati, K, Dejaco, C, Dougados, M, McInnes, I B, Sattar, N, Stamm, T A, Takeuchi, T, Trauner, M, van der Heijde, D S, Voshaar, M, Winthrop, K L, Ravelli, A, Betteridge, N, Burmester, G-R D R, Bijlsma, J W J, Bykerk, V, Caporali, R, Choy, E H, Codreanu, C, Combe, B, Crow, M K, de Wit, M, Emery, P, Fleischmann, R M, Gabay, C, Hetland, M L, Hyrich, K L, Iagnocco, A, Isaacs, J D, Kremer, J M, Mariette, X, Merkel, P, Mysler, E F, Nash, P, Nurmohamed, M T, Pavelka, K, Poor, G, Rubbert-Roth, A, Schulze-Koops, H, Strangfeld, A, Tanaka, Y & Smolen, J S 2022, ' Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions : an update ', Annals of the Rheumatic Diseases . https://doi.org/10.1136/ard-2022-222784
Annals of the Rheumatic Diseases. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases
Aletaha, D, Kerschbaumer, A, Kastrati, K, Dejaco, C, Dougados, M, McInnes, I B, Sattar, N, Stamm, T A, Takeuchi, T, Trauner, M, Van Der Heijde, D, Voshaar, M, Winthrop, K L, Ravelli, A, Betteridge, N, Burmester, G R R, Bijlsma, J W J, Bykerk, V, Caporali, R, Choy, E H, Codreanu, C, Combe, B, Crow, M K, De Wit, M, Emery, P, Fleischmann, R M, Gabay, C, Hetland, M L, Hyrich, K L, Iagnocco, A, Isaacs, J D, Kremer, J M, Mariette, X, Merkel, P, Mysler, E F, Nash, P, Nurmohamed, M T, Pavelka, K, Poor, G, Rubbert-Roth, A, Schulze-Koops, H, Strangfeld, A, Tanaka, Y & Smolen, J S 2023, ' Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions : an update ', Annals of the Rheumatic Diseases, vol. 82, no. 6, pp. 773–787 . https://doi.org/10.1136/ard-2022-222784
Annals of the Rheumatic Diseases. BMJ Publishing Group

BackgroundTargeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5450f45d4f38f87158cb07200a3b129
https://doi.org/10.1136/ard-2022-222784

Individual therapeutic DAS28-d

Autor: Michaela, Koehm, Matthew J, McIntosh, Michael W, Hofmann, Varghese, Abraham, Cem, Gabay, Ernest H, Choy, Arthur, Kavanaugh, Harald, Burkhardt, Frank, Behrens

Publikováno v: Rheumatology international. 40(5)

Assessment of individual therapeutic responses provides valuable information concerning treatment benefits in individual patients. We evaluated individual therapeutic responses as determined by the Disease Activity Score-28 joints critical difference

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bd498401a3c10fc32031d7c41edb16aa
https://pubmed.ncbi.nlm.nih.gov/32040761

Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study

Autor: Ernest H, Choy, Corrado, Bernasconi, Maher, Aassi, Jose Fernando, Molina, Oscar Massimiliano, Epis

Publikováno v: Arthritis Care & Research

Objective To compare clinical effectiveness between tocilizumab and tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and inadequate response to conventional synthetic disease‐modifying antirheumatic drugs initiatin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8bdb6362e03064258e8b65d8e47ada8a
https://pubmed.ncbi.nlm.nih.gov/28622454

T-cell costimulation and other directed therapies

Autor: Ernest H. Choy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::121bf6e9a37fe0286f045e9630f4727f
https://doi.org/10.1016/b978-0-323-09138-1.00059-0